- Home
- AIMD vs BIVI Comparison
AIMD vs BIVI Comparison
Compare AIMD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- BIVI
- Stock Information
- Founded
- AIMD 1984
- BIVI 2013
- Country
- AIMD United States
- BIVI United States
- Employees
- AIMD N/A
- BIVI N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- BIVI Health Care
- Exchange
- AIMD Nasdaq
- BIVI Nasdaq
- Market Cap
- AIMD 16.9M
- BIVI 14.2M
- IPO Year
- AIMD N/A
- BIVI N/A
- Fundamental
- Price
- AIMD $2.27
- BIVI $1.49
- Analyst Decision
- AIMD
- BIVI
- Analyst Count
- AIMD 0
- BIVI 0
- Target Price
- AIMD N/A
- BIVI N/A
- AVG Volume (30 Days)
- AIMD 37.4K
- BIVI 99.8K
- Earning Date
- AIMD 11-13-2025
- BIVI 11-10-2025
- Dividend Yield
- AIMD N/A
- BIVI N/A
- EPS Growth
- AIMD N/A
- BIVI N/A
- EPS
- AIMD N/A
- BIVI N/A
- Revenue
- AIMD $113,037.00
- BIVI N/A
- Revenue This Year
- AIMD N/A
- BIVI N/A
- Revenue Next Year
- AIMD N/A
- BIVI N/A
- P/E Ratio
- AIMD N/A
- BIVI N/A
- Revenue Growth
- AIMD 178.19
- BIVI N/A
- 52 Week Low
- AIMD $2.00
- BIVI $1.42
- 52 Week High
- AIMD $5.00
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- AIMD 28.33
- BIVI 34.70
- Support Level
- AIMD $2.59
- BIVI $1.42
- Resistance Level
- AIMD $3.16
- BIVI $1.66
- Average True Range (ATR)
- AIMD 0.24
- BIVI 0.10
- MACD
- AIMD -0.11
- BIVI -0.01
- Stochastic Oscillator
- AIMD 0.00
- BIVI 12.87
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.